Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5. - Wikidata - awgldk - TriplyDB

Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5.

Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5.

http://www.wikidata.org/entity/Q40072776

about

PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters.Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs.Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling.Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence.Modeling Drug Disposition and Drug-Drug Interactions Through Hypothesis-Driven Physiologically Based Pharmacokinetics: a Reversal Translation Perspective.Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s.The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance.

P2860

Q38664509-4C72BEB9-6943-4166-BEB4-C9B48C1C0249 Q38699135-F4EAEF6A-5929-4ACF-AEF0-D2189B5E7064 Q40431727-80FA5E0B-B0A7-4849-9765-A9BADC4ED504 Q46675919-6C5BBE16-3E64-4FC9-A84C-204832D1FB82 Q47813133-A7DCBFCC-7119-4069-8C8F-723FA7112C89 Q50076374-9DD20B85-DDE4-4E7C-8FBD-2BDC0915438A Q52637933-416EB544-7B57-4A86-9A10-843FA5F701E4 Q53233045-1C4B9EF0-C469-47E6-8822-82E00D74AB41

P2860

Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5.

http://www.wikidata.org/entity/Q40072776

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Systematic and quantitative as ...... isease on CYP2D6 and CYP3A4/5.

@en

type

label

Systematic and quantitative as ...... isease on CYP2D6 and CYP3A4/5.

@en

prefLabel

Systematic and quantitative as ...... isease on CYP2D6 and CYP3A4/5.

@en

P1433

Q40072776-5597C479-06BD-41CE-A5CE-F582877FD40C

P1476

Q40072776-70CB1547-0474-4753-93BE-B2F40849B882

P2093

Q40072776-1B133D88-97B1-4CCC-8BE5-72B337BBCB98

Q40072776-2B4FBF2F-4AD0-40E7-B136-6FFB7C1B4465

Q40072776-3F656181-158C-4537-93BA-353A2DDA0BFE

Q40072776-517BA960-86B7-4431-9C32-FC3D5C2B6664

Q40072776-6673AA74-5693-46DB-AC07-8C83D86293CB

Q40072776-968C8217-2B82-47F9-8EB9-6525623B3B1A

Q40072776-DD6FA2C5-45FA-406E-83A5-2F2C89EA2882

Q40072776-ECB6B995-BDC8-46E6-98C4-7232E1778CCA

P2860

Q40072776-0D6EB6B7-C522-4428-B537-36C59D0FC810

Q40072776-0DB9C129-A5AC-40CB-8BFE-FFF362D68A1E

Q40072776-177C9C9E-0DFD-47C4-8702-4564862DC935

Q40072776-28906638-6747-4C85-B9FD-6DEF51C19081

Q40072776-292ED8C1-598F-4F1C-840C-D3FEBAB02E84

Q40072776-30EBE8AB-963F-4E3E-A97B-7212B71FDC99

Q40072776-34895DA1-7F2B-4FF8-B79B-E0E8D9C0D0BD

Q40072776-38A8F5BC-0DC1-435C-94FA-63163B5E4033

Q40072776-38DC8DAF-10C5-438C-8F58-701C635B79DB

Q40072776-46B949FA-99B7-49BF-9A07-F74B3ED81ECE

P304

Q40072776-0FCFCEAC-8C61-417B-BCD0-318027C60FCC

P31

Q40072776-BEDEDEAA-EF2E-4FFA-A160-870EAB995F64

P356

Q40072776-D6C8D89B-527A-4B53-B6BD-016EB184563E

P407

Q40072776-3DD27C5E-9768-469A-8419-6920BA723C93

P433

Q40072776-5951D2B8-CE13-46FF-B106-C09EED13D6E5

P478

Q40072776-D679A9B7-D4EA-4B2F-B379-5444385F657C

P50

Q40072776-1A110645-892B-42AA-AECE-0C7BBE142E68

P577

Q40072776-8EDF0D11-F475-4F89-8BB3-C9CE3DF96A7B

P698

Q40072776-810B0D71-21EE-4E0E-AC58-BE974998EE35

P932

Q40072776-4ADC5B58-353B-4365-A76E-A99C14BE5C51

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Systematic and quantitative as ...... isease on CYP2D6 and CYP3A4/5.

@en

P2093

B Sun

http://www.w3.org/2001/XMLSchema#string

D R Abernethy

http://www.w3.org/2001/XMLSchema#string

I Zineh

http://www.w3.org/2001/XMLSchema#string

K Yoshida

http://www.w3.org/2001/XMLSchema#string

L Zhang

http://www.w3.org/2001/XMLSchema#string

P Zhao

http://www.w3.org/2001/XMLSchema#string

S-M Huang

http://www.w3.org/2001/XMLSchema#string

T D Nolin

http://www.w3.org/2001/XMLSchema#string

P2860

Predicting in vivo drug interactions from in vitro drug discovery data.

Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients.

The pharmacokinetics of nortriptyline in patients with chronic renal failure.

Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization.

CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.

Emerging evidence of the impact of kidney disease on drug metabolism and transport.

ESRD impairs nonrenal clearance of fexofenadine but not midazolam.

Public health consequences of chronic kidney disease.

Modeling and predicting drug pharmacokinetics in patients with renal impairment.

Albumin-drug interaction and its clinical implication.

P304

75-87

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CPT.337

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Amin Rostami-Hodjegan

P577

2016-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26800425

http://www.w3.org/2001/XMLSchema#string

P932

5024330

http://www.w3.org/2001/XMLSchema#string